<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95368</article-id><article-id pub-id-type="doi">10.26442/20751753.2020.10.200267</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Skin reactions to cardiac drugs: a clinical case</article-title><trans-title-group xml:lang="ru"><trans-title>Кожные реакции на кардиологические препараты: клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nevozinskaia</surname><given-names>Zofiia A.</given-names></name><name xml:lang="ru"><surname>Невозинская</surname><given-names>Зофия Анатольевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, врач-дерматовенеролог</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Piruzian</surname><given-names>Anastas L.</given-names></name><name xml:lang="ru"><surname>Пирузян</surname><given-names>Анастас Львович</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф., гл. науч. сотр</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Korsunskaia</surname><given-names>Irina M.</given-names></name><name xml:lang="ru"><surname>Корсунская</surname><given-names>Ирина Марковна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. лаб.</p></bio><email>marykor@bk.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Center for Theoretical Problems of Physicochemical Pharmacology</institution></aff><aff><institution xml:lang="ru">ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2020-10-15"><day>15</day><month>10</month><year>2020</year></pub-date><pub-date date-type="collection"><year>2020</year></pub-date><volume>22</volume><issue>10</issue><issue-title xml:lang="en">VOL 22, NO10 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 22, №10 (2020)</issue-title><fpage>80</fpage><lpage>82</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2020-10-15"><day>15</day><month>10</month><year>2020</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95368">https://consilium.orscience.ru/2075-1753/article/view/95368</self-uri><abstract xml:lang="en"><p>Drug-induced photodermatitis is an important problem in a doctor's practice. This is due to the fact that a number of drugs widely used in medicine can cause the development of photodermatitis - antibiotics and sulfonamides, non-steroidal anti-inflammatory drugs, antineoplastic drugs, diuretics, antihypertensive and antiarrhythmic drugs, antidiabetic and psychiatric drugs, tretinoin and isotretinoin, as well as some others. Drug-induced photodermatitis proceeds as phototoxic reactions. In this situation, medicinal substances in the skin can act as a photosensitizer. The pathological mechanism of development of phototoxic reactions involves both an accumulation in the skin of a substance that possess effect of a photosensitizer and the simultaneous effect of solar radiation on the skin. The photosensitizer causes rashes by increasing skin sensitivity to visible or ultraviolet part of the spectrum. This article describes the case of a 64-year-old patient who developed photodermatitis while taking amiodarone for a long time.</p></abstract><trans-abstract xml:lang="ru"><p>Фотодерматиты, вызванные применением лекарственных препаратов, являются важной и актуальной проблемой в практике врачей. Это связано с тем, что вызывать развитие фотодерматитов может целый ряд широко используемых в медицине лекарственных средств - антибиотики и сульфаниламиды, нестероидные противовоспалительные препараты, противоопухолевые препараты, диуретики, гипотензивные и антиаритмические препараты, антидиабетические и психиатрические средства, третиноин и изотретиноин, а также некоторые другие. Фотодерматиты, вызванные применением лекарственных средств, протекают по типу фототоксических реакций. Лекарственные вещества в данной ситуации в коже могут играть роль фотосенсибилизатора. Патомеханизм развития фототоксических реакций основан на накоплении в коже вещества, которое обладает свойствами фотосенсибилизатора, и одновременного воздействия на кожу солнечного излучения. Фотосенсибилизатор, повышая чувствительность кожи к видимой или ультрафиолетовой части спектра, приводит к развитию высыпаний. В своей статье мы описали случай 64-летнего пациента, у которого развился фотодерматит на фоне длительного приема амиодарона.</p></trans-abstract><kwd-group xml:lang="en"><kwd>photodermatitis</kwd><kwd>phototoxic reactions</kwd><kwd>amiodarone</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фотодерматит</kwd><kwd>фототоксические реакции</kwd><kwd>амиодарон</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wilm A, Berneburg M. Photoallergy. J Dtsch Dermatol Ges 2015; 13: 7-12.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: classification, evaluation and management. Br J Dermatol 2009; 161 (Suppl. 3): 61-8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Honari G. Photoallergy. Rev Environ Health. 2014; 29: 233-42.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6: 431-43.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ladizinski B, Elpern DJ. Dronaderone-induced phototoxicity. J Drugs Dermatol 2013; 12 (8): 946-7.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Maoz KB, Dvash S, Brenner S, Brenner S. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol 2009; 48 (12): 1398-400. DOI: 10.1111/j.1365-4632.2008.03819.x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg 2004; 8 (6): 424-31.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011; 34 (10): 821-37. DOI: 10.2165/11592780-000000000-00000</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jaworski K, Walecka I, Rudnicka L et al. Cutaneous adverse reactions of amiodarone. Med Sci Monit 2014; 20: 2369-72. DOI: 10.12659/MSM.890881</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bongard V, Marc D, Philippe V et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006; 13 (4): 315-9.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ammoury A, Michaud S, Paul C et al. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol 2008; 144 (1): 92-6. DOI: 10.1001/archdermatol.2007.25</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Yones SS, O'Donoghue NB, Palmer RA et al. Persistent severe amiodarone-induced photosensitivity. Clin Exp Dermatol 2005; 30 (5): 500-2.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Shah N, Warnakulasuriya S. Amiodarone-induced peri-oral photosensitivity. J Oral Pathol Med 2004; 33 (1): 56-8.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rappersberger K, Honigsmann H, Ortel B et al. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989; 93: 201-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298 (11): 1312-22.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ferguson J, Addo HA, Jones S et al. A study of cutanous photosensitivity induced by amiodarone. Br J Dermatol 1985; 113: 537-49.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2 (4): 253-62.</mixed-citation></ref></ref-list></back></article>
